Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions

Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).

FDA entrance sign 2016

The long-planned 'modernization' of the US FDA's Office of New Drugs is expected to nearly double OND's organizational chart. OND, housed within the Center for Drug Evaluation and Research, would add four offices overseeing review operations (for a total of nine) and 11 drug review divisions (for a total of 30).

The proposed structural changes – which are still somewhat in flux and are subject to further internal administrative review and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet